Last reviewed · How we verify
BRL 49653C
BRL 49653C is a drug that has been investigated for its potential therapeutic effects.
BRL 49653C is a drug that has been investigated for its potential therapeutic effects. Used for Phase 3 clinical trials for BRL 49653C have been conducted, but the specific indications are unclear..
At a glance
| Generic name | BRL 49653C |
|---|---|
| Also known as | Avandia, rosiglitazone |
| Sponsor | National Taiwan University Hospital |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Unfortunately, there is limited information available on the specific mechanism of action of BRL 49653C. Further research is needed to fully understand its effects on the body.
Approved indications
- Phase 3 clinical trials for BRL 49653C have been conducted, but the specific indications are unclear.
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of BRL 49653C in Non-insulin Dependent Diabetes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BRL 49653C CI brief — competitive landscape report
- BRL 49653C updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI